![Kanad D. Das](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kanad D. Das
Direttore/Membro del Consiglio presso
Oncomyx Therapeutics, Inc.
Profilo
Kanad D.
Das has worked as an Investment Director at Boehringer Ingelheim (Venture Capital) since 2018.
He also currently holds Director positions at Actym Therapeutics, Inc. and Oncomyx Therapeutics, Inc.
Posizioni attive di Kanad D. Das
| Società | Posizione | Inizio |
|---|---|---|
Oncomyx Therapeutics, Inc.
 Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Develops and operates software platform to orchestrate an immune response & treat cancer | Direttore/Membro del Consiglio | - |
Actym Therapeutics, Inc.
 Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immune-oncology therapies | Direttore/Membro del Consiglio | - |
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Investitore di Private Equity | 01/05/2018 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
6
Relazioni di 1° grado
3
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm targets companies operating in groundbreaking innovation including cancer, regenerative medicine, auto-immunity indications, digital solutions and infectious disease. It participaotes in seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes seat on the board of directors. | Finance |
Actym Therapeutics, Inc.
Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops immune-oncology therapies | Health Technology |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Develops and operates software platform to orchestrate an immune response & treat cancer | Technology Services |
